BIOMARIN PHARMACEUTICAL INC Deferred Offering Costs
BIOMARIN PHARMACEUTICAL INC (BMRN) had Deferred Offering Costs of $9.26 million as of 2015-09-30, per its 10-Q filed 2015-11-02.
Discontinued › Balance Sheet › Assets › Assets, Current › Deferred Costs, Current
us-gaap:DeferredOfferingCosts · last filed 2015-11-02
- 2015-09-30: Deferred Offering Costs $9.26M.
- 2015-06-30: Deferred Offering Costs $10.09M.
- 2015-03-31: Deferred Offering Costs $10.91M.
- 2014-12-31: Deferred Offering Costs $11.76M.
| Period end | Deferred Offering Costs |
|---|---|
| 2015-09-30 | $9.26M 10-Q · filed 2015-11-02 |
| 2015-06-30 | $10.09M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $10.91M 10-Q · filed 2015-05-05 |
| 2014-12-31 | $11.76M 10-Q · filed 2015-11-02 |
| 2014-09-30 | $12.61M 10-Q · filed 2014-10-28 |
| 2014-06-30 | $13.44M 10-Q · filed 2014-07-31 |
| 2014-03-31 | $14.36M 10-Q · filed 2014-05-02 |
| 2013-12-31 | $15.37M 10-K · filed 2015-03-02 |
| 2012-12-31 | $3.67M 10-K · filed 2014-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |